Current CEO Jan Alenfall will, for a period of at least six months continue to work in the company in the position of Chief Scientific Officer
Follicum has recruited Dr Kim Arvid Nielsen as new CEO, taking office on April 6, 2021. He has experience in business development, investor relations and drug development from leading positions in both small and large pharmaceutical companies. At the same time, Follicum is establishing a position of Chief Scientific Officer. The changes are aimed to strengthen the company's organisation to keep in step with the progress made in its pharmaceutical projects.
Follicum's current CEO Jan Alenfall will, for a period of at least six months continue to work in the company in the position of Chief Scientific Officer. The company's R&D Director, Maria Ekblad, will remain in her current role.
”We are delighted to welcome Kim Arvid Nielsen as Follicum’s new CEO. His solid commercial experience and expertise in drug development will strengthen the company's ability to take advantage of the opportunities that a positive outcome in the Phase II study of FOL-005 can bring. Jan Alenfall's contribution to the company during his 10 years as CEO is invaluable, and we are pleased that he has chosen to take up the position as Chief Scientific Officer,” said Gun-Britt Fransson, Chairman of the Board of Follicum.
Kim Arvid Nielsen is a physician and executive master of business administration with extensive experience in business development, investor relations and drug development. He has previously held senior roles in smaller life science enterprises as well as global pharmaceutical companies, including Cytovac, Scandion Oncology, Serendex, Bayer, Pharmion, Ferrosan and Serono Nordic.
"I see great medical and commercial potential in Follicum's unique tissue repairing peptides and will do my utmost to contribute to the company's continued value creation based on my previous experience in business and drug development," said Kim Arvid Nielsen, incoming CEO of Follicum.
“As Follicum's projects advances, new demands are placed on our organization. I am pleased with the Board's decision to expand the management team and recruit a new CEO to take the lead on the company's overriding strategic development, while I can now focus wholeheartedly on our preclinical and clinical drug development,” said Jan Alenfall, CEO, Follicum.